(Q37805216)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Aerosol drug delivery: developments in device design and clinical use (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Myrna B Dolovich

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

29 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

9770

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1032-1045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

Control of asthma by aerosols

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Advances in aerosols: adult respiratory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone pr

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Clinical models to compare the safety and efficacy of inhaled corticosteroids in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Systemic effect comparisons of six inhaled corticosteroid preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

New delivery systems and propellants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Influence of the Metering Chamber Volume and Actuator Design on the Aerodynamic Particle Size of a Metered Dose Inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Real-world assessment of a metered-dose inhaler with integrated dose counter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

How do patients determine that their metered-dose inhaler is empty?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Efficacy Response of Inhaled HFA-Albuterol Delivered via the Breath-Actuated Autohaler™ Inhalation Device Is Comparable to Dose in Patients with Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Accuracy of three electronic monitors for metered-dose inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Aerosol delivery to young children by pMDI-spacer: is facemask design important?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Aerosol therapy: the special needs of young children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Assessment of inhalation technique in children in general practice: increased risk of incorrect performance with new device

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Advancements in dry powder delivery to the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Bioengineering of therapeutic aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Active and intelligent inhaler device development.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

In vitro, ex vivo, in vivo veritas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Inspiratory flow rates at different levels of resistance in elderly COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Can patients use all dry powder inhalers equally well?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Improving drug delivery from medical nebulizers: the effects of increased nebulizer flow rates and reservoirs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Rationale for the selection of an aerosol delivery system for gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Four hours of continuous albuterol nebulization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Facemasks and aerosol delivery in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Facemask design, facial deposition, and delivered dose of nebulized aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Continuous bronchodilator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparison of two methods of delivering continuously nebulized albuterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Continuous versus intermittent beta-agonists for acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparison of twenty three nebulizer/compressor combinations for domiciliary use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

The influence of fluid physicochemical properties on vibrating-mesh nebulization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Adaptive Aerosol Delivery (AAD) technology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Aerosol delivery through nasal cannulas: an in vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

A miniaturized nebulization catheter for improved gene delivery to the mouse lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Nanomagnetosols: magnetism opens up new perspectives for targeted aerosol delivery to the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Targeted delivery of magnetic aerosol droplets to the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

The effect of heliox on nebulizer function using a beta-agonist bronchodilator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

How best to deliver aerosol medications to mechanically ventilated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

The mask for noninvasive ventilation: principles of design and effects on aerosol delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Trivalent intranasal influenza vaccine, live

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Respiratory administration of measles vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- d

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Progress and prospects: gene therapy clinical trials (part 2).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Pulmonary delivery of nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Inadequate skill of healthcare professionals in using asthma inhalation devices

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

Medication adherence issues in patients treated for COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960926-9

7 January 2021

10.1016/S0140-6736(10)60926-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21036392%20AND%20SRC:MED&resulttype=core&format=json